Evotec Se (EVO)

$3.48 +0.11 (3.26%)
Market Cap 1.24B
Revenue (ttm) 862.40M
Net Income (ttm) -212.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.60%
Debt to Equity Ratio 0.55
Volume 85,900
Avg Vol 68,976
Day's Range N/A - N/A
Shares Out 355.11M
Stochastic %K 46%
Beta 1.72
Analysts Sell
Price Target $5.67

Company Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; centra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 49 40 560 81 0
Address:
Essener Bogen 7, Hamburg, Germany
IshfaaqPeerally
IshfaaqPeerally Sep. 8 at 1:58 PM
Evolution repurchased 377,000 last week. I'm sure this is the biggest weekly repurchased I've seen for this company. $EVVTY $EVO
0 · Reply
WireX
WireX Sep. 7 at 1:50 PM
$EVO - Evotec is a leader in targeted protein degradation (TPD), a strategy that addresses the downstream effects of misfolding by removing disease-causing proteins. This approach is central to its partnerships with companies like Bristol Myers Squibb.
0 · Reply
WireX
WireX Sep. 7 at 1:47 PM
$EVO Evotec was an early adopter of incoroporating AlphFold AlphaFold has fundamentally changed medical research by providing a powerful and rapid tool for predicting protein structures, accelerating drug discovery, and deepening the understanding of disease mechanisms The development of AlphaFold, particularly its second and third versions, has been described as a revolution comparable in importance to the advent of genomics. Not getting a lot of press but the latest versions of AlphaFold are about to change medicine. Many are now incorporating it but this small player offers the most bang for the buck if they get it right.
0 · Reply
Ferulic
Ferulic Aug. 26 at 7:17 PM
$EVO https://www.sandoz.com/sandoz-signs-non-binding-term-sheet-evotec-se-acquire-its-just-evotec-biologics-house-development/ Halozyme should seize this unique opportunity and buy EVOTEC! €6 is a great bargain! Just a few months ago, the price was €11. Those who are too late will not be able to buy growth at a low price, or will Novo Nordisk, Sandaoz, Genmab, or finally Halozyme come along?
0 · Reply
IshfaaqPeerally
IshfaaqPeerally Aug. 18 at 8:13 AM
Evolution repurchased 90,000 shares the day the stock dropped 10%. A total of 248,000 last week vs an average around 150,000-175,000 previously. That's excellent and opportunistic capital allocation. $EVVTY $EVO
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Evotec ( $EVO ), setting the rating to Buy with a target price of 8 → 7.
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:47 AM
$EVO (+3.5% pre) Evotec Strikes $300M Biologics Facility Deal with Sandoz, Secures Future Revenue Streams https://ooc.bz/l/71755
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:14 AM
$EVO The proposed ~$300 million cash consideration provides immediate liquidity, enabling improved capital efficiency and less balance-sheet drag. Evotec also retains future upside through potential development, milestone, and royalty payments. Non-Binding Agreement: The agreement remains subject to employee consultations, final contracts, and regulatory approvals. Failure in any stage could delay or derail the deal.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:13 AM
$EVO Evotec SE and Sandoz AG have signed a non-binding term sheet for the potential sale of the Just – Evotec Biologics EU facility in Toulouse, France
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 30 at 10:21 AM
WATCHLIST JUL 30 2025 $BTC Anthony Scaramucci Thanks 'Crypto Mom' Hester Pierce For 'Hard-Fought Contribution' After SEC Approves In-Kind Redemption For Bitcoin, Ethereum ETFs $EVO Evotec To Sell Just-Evotec Biologics Toulouse Site To Sandoz For $300M Cash Plus Royalties, Marking Shift To Asset-Lighter Model $QQQ Starbucks Turnaround Under New CEO Brian Niccols Gains Momentum, Preps For Protein Push As 'Back to Starbucks' Investments Squeeze Q3 Profits $VRT Vertiv shares are trading higher after reporting better-than-expected Q2 EPS and sales and raising FY25 EPS and sales guidance above estimates. $MDGL Madrigal Licenses New GLP-1 Drug to Boost MASH Treatment Pipeline With Once-Daily Oral Combo in Sight
0 · Reply
Latest News on EVO
Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 2:43 PM EDT - 25 days ago

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Aug 13, 2025, 1:25 AM EDT - 26 days ago

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Evotec SE to announce first half-year results 2025 on 13 August 2025

Aug 6, 2025, 4:15 AM EDT - 4 weeks ago

Evotec SE to announce first half-year results 2025 on 13 August 2025

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

Jul 30, 2025, 1:45 AM EDT - 5 weeks ago

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Jul 30, 2025, 1:40 AM EDT - 5 weeks ago

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec: Recovery Seems To Be Beginning

Jul 23, 2025, 5:43 AM EDT - 6 weeks ago

Evotec: Recovery Seems To Be Beginning

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 21, 2025, 8:49 AM EDT - 7 weeks ago

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BULL

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Jul 21, 2025, 6:10 AM EDT - 7 weeks ago

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

Jul 21, 2025, 5:50 AM EDT - 7 weeks ago

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

Jun 25, 2025, 1:50 AM EDT - 2 months ago

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

May 7, 2025, 1:50 AM EDT - 4 months ago

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

Evotec SE (EVO) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:15 AM EDT - 4 months ago

Evotec SE (EVO) Q1 2025 Earnings Call Transcript

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

May 6, 2025, 1:20 AM EDT - 4 months ago

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

Apr 29, 2025, 4:30 AM EDT - 4 months ago

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Apr 24, 2025, 1:50 AM EDT - 4 months ago

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Evotec SE (EVO) Q4 2024 Earnings Call Transcript

Apr 17, 2025, 2:24 PM EDT - 5 months ago

Evotec SE (EVO) Q4 2024 Earnings Call Transcript

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Apr 17, 2025, 1:45 AM EDT - 5 months ago

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

Apr 10, 2025, 6:00 AM EDT - 5 months ago

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Mar 4, 2025, 1:45 AM EST - 6 months ago

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

BMY

Evotec Announces Change in Management Board

Feb 26, 2025, 2:00 AM EST - 6 months ago

Evotec Announces Change in Management Board

Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner

Feb 19, 2025, 7:55 AM EST - 7 months ago

Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Jan 22, 2025, 2:00 AM EST - 8 months ago

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec: Some Recovery Has Come, But Much More Is Expected

Dec 29, 2024, 12:30 PM EST - 9 months ago

Evotec: Some Recovery Has Come, But Much More Is Expected

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Dec 11, 2024, 2:00 AM EST - 9 months ago

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Comment on Withdrawn Non-Binding Offer

Nov 22, 2024, 11:15 AM EST - 10 months ago

Comment on Withdrawn Non-Binding Offer

Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 10 months ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

HALO

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Nov 22, 2024, 8:35 AM EST - 10 months ago

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

HALO

Halozyme CEO: Evotec Is Poised for Growth

Nov 18, 2024, 4:00 PM EST - 10 months ago

Halozyme CEO: Evotec Is Poised for Growth

HALO

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Nov 18, 2024, 7:00 AM EST - 10 months ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

HALO

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Nov 15, 2024, 12:56 PM EST - 10 months ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

HALO

Comment on Media Report

Nov 14, 2024, 5:30 PM EST - 10 months ago

Comment on Media Report

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Nov 14, 2024, 4:15 PM EST - 10 months ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

HALO

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

Nov 14, 2024, 4:09 PM EST - 10 months ago

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

HALO

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

Nov 11, 2024, 10:52 AM EST - 10 months ago

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

Evotec SE (EVO) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:11 PM EST - 10 months ago

Evotec SE (EVO) Q3 2024 Earnings Call Transcript

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Nov 6, 2024, 1:20 AM EST - 10 months ago

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

Nov 5, 2024, 1:50 AM EST - 10 months ago

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Oct 30, 2024, 3:30 AM EDT - 11 months ago

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Oct 23, 2024, 2:00 AM EDT - 11 months ago

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

Sep 26, 2024, 10:33 AM EDT - 1 year ago

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

NVO

Evotec and Novo Nordisk forge technology development partnership

Sep 26, 2024, 2:14 AM EDT - 1 year ago

Evotec and Novo Nordisk forge technology development partnership

NVO

Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

Sep 26, 2024, 2:00 AM EDT - 1 year ago

Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

Sep 20, 2024, 9:45 AM EDT - 1 year ago

Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

Scientist.com and Evotec Partner to Accelerate Drug Discovery and Development

Sep 9, 2024, 7:55 AM EDT - 1 year ago

Scientist.com and Evotec Partner to Accelerate Drug Discovery and Development

Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

Evotec: Weak Performance, But Long-Term Potential Is There

Aug 30, 2024, 10:15 AM EDT - 1 year ago

Evotec: Weak Performance, But Long-Term Potential Is There

Evotec SE (EVO) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 12:36 PM EDT - 1 year ago

Evotec SE (EVO) Q2 2024 Earnings Call Transcript

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Aug 14, 2024, 1:30 AM EDT - 1 year ago

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Aug 13, 2024, 2:00 AM EDT - 1 year ago

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

Aug 8, 2024, 1:50 AM EDT - 1 year ago

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

IshfaaqPeerally
IshfaaqPeerally Sep. 8 at 1:58 PM
Evolution repurchased 377,000 last week. I'm sure this is the biggest weekly repurchased I've seen for this company. $EVVTY $EVO
0 · Reply
WireX
WireX Sep. 7 at 1:50 PM
$EVO - Evotec is a leader in targeted protein degradation (TPD), a strategy that addresses the downstream effects of misfolding by removing disease-causing proteins. This approach is central to its partnerships with companies like Bristol Myers Squibb.
0 · Reply
WireX
WireX Sep. 7 at 1:47 PM
$EVO Evotec was an early adopter of incoroporating AlphFold AlphaFold has fundamentally changed medical research by providing a powerful and rapid tool for predicting protein structures, accelerating drug discovery, and deepening the understanding of disease mechanisms The development of AlphaFold, particularly its second and third versions, has been described as a revolution comparable in importance to the advent of genomics. Not getting a lot of press but the latest versions of AlphaFold are about to change medicine. Many are now incorporating it but this small player offers the most bang for the buck if they get it right.
0 · Reply
Ferulic
Ferulic Aug. 26 at 7:17 PM
$EVO https://www.sandoz.com/sandoz-signs-non-binding-term-sheet-evotec-se-acquire-its-just-evotec-biologics-house-development/ Halozyme should seize this unique opportunity and buy EVOTEC! €6 is a great bargain! Just a few months ago, the price was €11. Those who are too late will not be able to buy growth at a low price, or will Novo Nordisk, Sandaoz, Genmab, or finally Halozyme come along?
0 · Reply
IshfaaqPeerally
IshfaaqPeerally Aug. 18 at 8:13 AM
Evolution repurchased 90,000 shares the day the stock dropped 10%. A total of 248,000 last week vs an average around 150,000-175,000 previously. That's excellent and opportunistic capital allocation. $EVVTY $EVO
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Evotec ( $EVO ), setting the rating to Buy with a target price of 8 → 7.
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:47 AM
$EVO (+3.5% pre) Evotec Strikes $300M Biologics Facility Deal with Sandoz, Secures Future Revenue Streams https://ooc.bz/l/71755
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:14 AM
$EVO The proposed ~$300 million cash consideration provides immediate liquidity, enabling improved capital efficiency and less balance-sheet drag. Evotec also retains future upside through potential development, milestone, and royalty payments. Non-Binding Agreement: The agreement remains subject to employee consultations, final contracts, and regulatory approvals. Failure in any stage could delay or derail the deal.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:13 AM
$EVO Evotec SE and Sandoz AG have signed a non-binding term sheet for the potential sale of the Just – Evotec Biologics EU facility in Toulouse, France
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 30 at 10:21 AM
WATCHLIST JUL 30 2025 $BTC Anthony Scaramucci Thanks 'Crypto Mom' Hester Pierce For 'Hard-Fought Contribution' After SEC Approves In-Kind Redemption For Bitcoin, Ethereum ETFs $EVO Evotec To Sell Just-Evotec Biologics Toulouse Site To Sandoz For $300M Cash Plus Royalties, Marking Shift To Asset-Lighter Model $QQQ Starbucks Turnaround Under New CEO Brian Niccols Gains Momentum, Preps For Protein Push As 'Back to Starbucks' Investments Squeeze Q3 Profits $VRT Vertiv shares are trading higher after reporting better-than-expected Q2 EPS and sales and raising FY25 EPS and sales guidance above estimates. $MDGL Madrigal Licenses New GLP-1 Drug to Boost MASH Treatment Pipeline With Once-Daily Oral Combo in Sight
0 · Reply
MGeronimo
MGeronimo Jul. 26 at 4:47 PM
$EVO ON AT 4.16
0 · Reply
wolfofharcourt
wolfofharcourt Jul. 25 at 8:05 AM
$EVO Kepler Cheuvreux rates Buy, PT SEK 1,075
0 · Reply
LewisDaKat
LewisDaKat Jul. 21 at 9:25 PM
News Article Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance https://marketwirenews.com/news-releases/evotec-se-adjusts-revenue-guidance-while-confirming--7117362910629727.html $EVO
0 · Reply
BuyNow_SellLater
BuyNow_SellLater Jul. 21 at 12:22 PM
$EVO just when I was starting to think there was hope
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 21 at 12:15 PM
$EVO (-12.9% pre) Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance https://ooc.bz/l/70582
0 · Reply
DonCorleone77
DonCorleone77 Jul. 21 at 10:34 AM
$EVO Evotec cuts FY25 revenue view to EUR 760M-EUR 800M from EUR 840M-EUR 880M -- Backs FY25 adjusted EBITDA view EUR 30M-EUR 50M.
0 · Reply
Arcides
Arcides Jul. 16 at 1:11 AM
$EVO base beginning to look good, volatility compressing.
0 · Reply
MGeronimo
MGeronimo Jul. 15 at 8:29 PM
$EVO ASTRA ZENECA PARTNERSHIP
0 · Reply
MGeronimo
MGeronimo Jul. 15 at 8:24 PM
$EVO IN AT 4.20 2x normal
0 · Reply
ChartBandit02
ChartBandit02 May. 27 at 2:01 PM
$EVO oh no
0 · Reply
ChartBandit02
ChartBandit02 May. 27 at 12:04 PM
$EVO so why is it going straight down now ?
0 · Reply
witdiligence
witdiligence May. 26 at 9:38 AM
$EVO $EVVTY it's a matter of waiting for the tide to turn. The company has a strong moat and feels like a no-brainer at these levels. It reminds me of $DKNG, which traded near all-time lows for a while before staging a strong comeback—despite social media outrage over the CEO’s use of the company jet for personal trips and widespread calls to short the stock to zero. The only arguments that matter should always be: LEADERSHIP - EXECUTION - PRODUCT As long as they align, it is only a matter of time.
2 · Reply